

**Oregon Prescription Drug Monitoring Program Advisory Commission**

**July 18<sup>th</sup>, 2014 Meeting Minutes**

1:00 PM to 4:00 PM

Portland State Office Building

800 NE Oregon Street, Room 918

Portland, OR 97232

**ATTENDEES:**

**Advisory Commission Present:** Mike Millard, Larisa Jeffries, Lindsay Jenkins, Sara Love, Al Turner, Mark Williams

**Advisory Commission Absent:** Chris Apgar, Bill Jordan, Tracy Muday, Karen Wheeler

**OHA Staff:** Todd Beran, Lisa Millet, Dagan Wright

**Guests:** Jay Anderson, Thomas Greenwood, Michael Hernandez, David Lehrfeld, John Mcilveen, Alan Perry

Decisions
1. The meeting minutes from April 2014 were approved as written.

Action Items	Assigned	Status
1. Consult with Advisory Commission regarding pick lists for provider board certification and clinical practice specialty.	Beran	In process

**INTRODUCTIONS**

Millard called the meeting to order at 1:15 p.m. Attendees introduced themselves.

**OLD BUSINESS**

The meeting minutes were reviewed and approved as written – see Decision 1.

**NEW BUSINESS**

**a. Review quarterly metrics**

Beran presented highlights of the quarterly reports. He noted that from the first to second quarters in 2014, there was an eight percent increase in queries conducted. This is largely due to additional queries conducted by office support staff who have been delegated by providers and pharmacists to access patient information.

Approved 10/17/2014

**b. BJA grant update**

Beran stated that two outreach specialists were hired in June 2014. Their focus is to sign up the remaining 38 percent of the 4,000 most frequent prescribers who have not yet signed up for a PDMP account.

Beran reported that a prescriber dashboard is in the development process with the system vendor. The dashboard reports will contain a line list of patients who meet one or more of the following high-risk overdose indicators: 1) patients with prescriptions from four or more prescribers and filled at four or more pharmacies within a 6-month time frame, 2) patients with opioid prescriptions at or greater than 120 morphine equivalent doses per day, 3) patients with methadone prescriptions at or greater than 40 milligrams per day, 4) patients receiving opioid and benzodiazepine prescriptions concurrently, and 5) patients prescribed opioids for three or more consecutive months. Dashboards will denote which of these indicators were met for each patient listed. The names of the patients will be hyperlinked so a system user can click on the name to pull up a detailed 6-month report on that patient to examine potential risk factors.

Beran reported that Program Design and Evaluation Services (PDES) has conducted six key informant interviews with a variety of clinic and health system administrative staff to assess how PDMP use policies may be implemented into practice guidelines. PDES has also identified a methadone clinic and a healthcare system to conduct patient record reviews to assess how use of the PDMP might impact patient care. The next step is to establish chart review protocols.

**c. Discuss collection of provider specialty**

Beran presented a draft proposal of a consolidated pick list of provider specialties from which system users will choose when applying for a PDMP account – see the attached handout. He noted that system users who already have an account will be prompted to update their profiles. Williams questioned the need for a “Veteran Affairs” option. Members agreed that a veteran affairs designation will not provide the detail intended for collecting specialty data. Millard suggested adding “Community Pharmacy” and “Ambulatory Care” options. Love suggested deleting “Occupational Medicine” since it is essentially covered under the larger category of “Physical Med & Rehab.” Beran will redistribute the list to Advisory Commission members for any additional input. Responses are due no later than close of business July 25.

**d. Discuss overdose report**

Wright presented an overview of the Drug Overdose Deaths, Hospitalizations, Abuse and Dependency among Oregonians report. He highlighted sections of the report that present rate differentials when comparing fatal and nonfatal prescription drug overdose among the entire population versus the number of individuals exposed to particular drugs

through prescriptions dispensed. He also highlighted how incidences of overdose increase exponentially when looking beyond primary cause for specific prescription drugs and when examining incidences of abuse and dependency. A copy of the report is located at [http://www.orpdmp.com/orpdmpfiles/PDF\\_Files/Reports/Oregon\\_Overdose\\_Report.pdf](http://www.orpdmp.com/orpdmpfiles/PDF_Files/Reports/Oregon_Overdose_Report.pdf).

**e. Discuss CDC overdose grant proposal**

Beran stated the grant proposal to CDC was accepted and is under review with an expected award notification date sometime on August 2014. The two focal grant strategies to prevent prescription drug overdose are 1) to enhance and maximize the PDMP and 2) to evaluate laws, policies, and regulations related to preventing prescription drug overdose. The initial phase of the evaluation process is to convene a cross-sector stakeholder workgroup to identify the laws, policies, and regulations to be evaluated. Those suggested by the CDC in the grant announcement will be considered during this phase. Once these are identified, sub-workgroups will be formed with the appropriate stakeholder group representatives to evaluate each law, policy, or regulation as they relate to Oregon. Millet stated that the program expects the CDC will direct the evaluation process.

**OPEN ISSUES**

Love and Millard requested clarification on their length of term as reappointed Advisory Commission members. Beran clarified that terms are four years in length.

Turner asked if medical marijuana data might be collected in the PDMP. Beran stated that while medical marijuana is a Schedule II drug in Oregon, it is not dispensed by pharmacies so data cannot be collected by the PDMP. Millard added that if a pharmacy were to dispense medical marijuana, the facility would lose its DEA license.

**PUBLIC COMMENT**

No public comments were made.

**NEXT MEETING DATE**

The next PDMP Advisory Commission meeting will be on Friday, October 17<sup>th</sup>, 2014 in room 918 at the Portland State Office Building.

**ADJOURNMENT**

The meeting was adjourned at 3:00 PM.